Pembrolizumab Dosing Schedules for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well pembrolizumab given every 12 weeks works compared to every 3 weeks in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab every 12 weeks may provide similar disease control with fewer treatments for patients with non-small cell lung cancer when compared to every 3 weeks. Demonstrating that 12 week dosing is as effective as 3 week dosing may also have a significant impact when considering the cost required for these medications.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on high-dose corticosteroids, you may need to stop or adjust them, as only low-dose prednisone is allowed for certain conditions.
Is pembrolizumab safe for humans?
Pembrolizumab has been studied in various conditions, including melanoma and non-small cell lung cancer. Common side effects include fatigue, cough, nausea, and rash, while more serious immune-related side effects can include lung inflammation, liver inflammation, and thyroid issues. Despite these risks, the benefits of pembrolizumab in treating life-threatening conditions have been considered to outweigh the potential side effects.12345
How is pembrolizumab different from other drugs for non-small cell lung cancer?
What data supports the effectiveness of the drug pembrolizumab for non-small cell lung cancer?
Pembrolizumab has shown clinical activity in various solid tumors, including non-small cell lung cancer, and is approved for second-line treatment in PD-L1-positive cases. It has demonstrated robust antitumor activity and manageable safety in patients with advanced solid tumors, supporting its use in non-small cell lung cancer.134510
Who Is on the Research Team?
Grace Dy, MD
Principal Investigator
Roswell Park Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults with non-small cell lung cancer who can be treated with pembrolizumab, have stable organ function, and an ECOG performance status of <=2. They must have responded to at least 6 months of pembrolizumab treatment without disease progression. Pregnant women or those on high-dose steroids for brain metastases are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pembrolizumab IV over 30 minutes every 3 weeks or every 12 weeks for up to 24 months
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
Pembrolizumab is already approved in United States, European Union, United Kingdom for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor